Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:47:53.940Z.
Calculation as of: 2026-10-06T18:47:53.940Z.
Quote observation: 2026-10-06T18:44:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8188a044afb190b383642178377b3b21d317b4c37addc3eac3f31d1e137b7514
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Seer, Inc.
Market Cap
$121.23M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Seer, Inc. (SEER) | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.39M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.38M | N/A |
| BGM Group Ltd. (BGM)vs › | $119.26M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.23M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.90M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.14M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.58M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
